Summary
Dr. Stephanie Venn-Watson dives deep into the metabolic pathways affected by C15:0 on The Metabolic Link. She explains how pentadecanoic acid activates AMPK and inhibits mTOR, sharing activity profiles with longevity drugs like rapamycin and metformin. The discussion covers C15:0's effects on metabolic markers, its role in Sardinian longevity zones, and why she believes it qualifies as a newly discovered essential fatty acid.
Key Points
- C15:0 activates AMPK and inhibits mTOR, mimicking key longevity drug pathways
- The fatty acid shares activity profiles with rapamycin and metformin in cell studies
- C15:0 targets over 30 clinically relevant metabolic pathways
- People in longevity zones like Sardinia have significantly higher C15:0 levels
- Venn-Watson argues C15:0 meets the criteria for essential fatty acid status
- The metabolic effects suggest benefits for insulin sensitivity and inflammation
Key Moments
C15:0 mimics longevity drug pathways
Venn-Watson explains how C15:0 activates AMPK and inhibits mTOR, sharing activity profiles with longevity drugs like rapamycin.
"you know, molecules like C15. So it's a really nice toolbox for longevity. Yeah. And in regard to longevity, I think there was a paper, if I remember correct, where it was compared to rapamycin, metformin and a carbose, I think. So there was some like comparative studies on that. Maybe explain like, and I think there was using a human cell line. So maybe explain some of the longevity studies comparing it"
